Table 1.
FGFR alteration types and frequency
| Target (alteration rate %) | Aberration (frequency %) | Cancer (frequency %**) |
|---|---|---|
| FGFR1 (3.5%) | Amplification (89%) Mutation (8%) Other* (2%) |
Breast (13.8%), urothelial (8.7%), ovarian/fallopian (4.7%), neuroendocrine (3.7%), glioma (3.5%), non-small cell lung (2.7%), sarcoma (2.5%), colorectal (2.4%) |
| FGFR2 (1.5%) | Amplification (49%) Mutation (18%) Fusion (15%) Other* (18%) |
Endometrial (7.5%), cholangiocarcinoma (6.1%), gastric/GE junction (3.7%), breast (2.3%) |
| FGFR3 (2.0%) | Amplification (30%) Mutation (44%) Fusion (15%) Other* (11%) |
Urothelial (22.2%), glioma (4.2%), endometrial (2.5%), pancreatic exocrine (2.3%), renal cell (2.3%) |
| FGFR4 (0.5%) | Amplification (78%) Other* (22%) |
Renal cell (1.1%), non-small cell lung (1.0%) |
*Other rare aberrations. **Cancers with a frequency < 2% are not listed in the table. GE, Gastroesophageal.